Rafael A. Alonso

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Journal: Journal for immunotherapy of cancer
Published: February 25, 2026

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Journal: HemaSphere
Published: December 23, 2025

Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis.

Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis.

Journal: Biomedicines
Published: October 16, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances
Published: September 18, 2025

GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia.

GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia.

Journal: Cytotherapy
Published: May 09, 2025

The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.

The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 06, 2025

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.

Journal: Blood
Published: January 13, 2025

Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy.

Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy.

Journal: Microbiome
Published: June 11, 2024

A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis.

A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis.

Journal: Cancers
Published: April 08, 2024

Different Mutational Profiles of Subcutaneous Panniculitis-like T-cell Lymphoma and Lupus Panniculitis: An Additional Case Series.

Different Mutational Profiles of Subcutaneous Panniculitis-like T-cell Lymphoma and Lupus Panniculitis: An Additional Case Series.

Journal: Actas dermo-sifiliograficas
Published: December 04, 2023

Presence of Epstein-Barr virus (EBV) antigens detected by sensitive methods has no influence on local immune environment in diffuse large B cell lymphoma.

Presence of Epstein-Barr virus (EBV) antigens detected by sensitive methods has no influence on local immune environment in diffuse large B cell lymphoma.

Journal: Cancer immunology, immunotherapy : CII
Published: September 07, 2023

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Journal: Haematologica
Published: August 25, 2023
Showing 1-12 of 61

Last Updated: 09/26/2026